North America Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024

List of Tables

The North America Diabetic Neuropathy Treatment Market would witness market growth of 6.6% CAGR during the forecast period (2024-2031).

The US market dominated the North America Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $1,993 million by 2031. The Canada market is experiencing a CAGR of 9% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 8.1% during (2024 - 2031).

An area of notable progress in the management of diabetic neuropathy pertains to the creation of innovative pharmacological interventions. Several medications have been approved for this purpose, including anticonvulsants, antidepressants, and opioids.

Additionally, these approaches include physical therapy, occupational therapy, and lifestyle modifications such as diet and exercise. The primary objectives are to enhance muscular strength and flexibility, alleviate pain and discomfort, and elevate the quality of life for those afflicted with diabetic neuropathy.

According to the National Library of Medicine, diabetes mellitus is particularly significant in Mexico, where it ranks as the sixth highest for the number of adults affected, with 12.8 million individuals diagnosed with the disease in 2019. This number is projected to rise significantly, reaching an estimated 22.3 million by the year 2045. The Mexican government implemented a program (El Sistema de Vigilancia Epidemiologica Hospitalaria de Diabetes Mellitus Tipo 2, SVEHDMT2) to monitor hospital attendance by people suffering from type 2 diabetes mellitus.

Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy.Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

Abbott Laboratories
Eli Lilly And Company
Pfizer, Inc.
Lupin Limited
Astellas Pharma, Inc.
Glenmark Pharmaceuticals Limited
Boehringer Ingelheim International GmbH
Novartis AG
McKesson Corporation
GlaxoSmithKline PLC (GSK)

North America Diabetic Neuropathy Treatment Market Report Segmentation

By Distribution Channel

Hospitals Pharmacies
Retail Pharmacies
Others

By Drug Class

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Antidepressants
Opioid
Capsaicin
Others

By Disorder Type

Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy

By Country

US
Canada
Mexico
Rest of North America

Chapter 1.Market Scope & Methodology

1.1Market Definition
1.2Objectives
1.3Market Scope
1.4Segmentation
- 1.4.1North America Diabetic Neuropathy Treatment Market, by Distribution Channel
- 1.4.2North America Diabetic Neuropathy Treatment Market, by Drug Class
- 1.4.3North America Diabetic Neuropathy Treatment Market, by Disorder Type
- 1.4.4North America Diabetic Neuropathy Treatment Market, by Country
1.5Methodology for the research

Chapter 2.Market at a Glance

2.1Key Highlights

Chapter 3.Market Overview

3.1Introduction
- 3.1.1Overview
  - 3.1.1.1Market Composition and Scenario
3.2Key Factors Impacting the Market
- 3.2.1Market Drivers
- 3.2.2Market Restraints
- 3.2.3Market Opportunities
- 3.2.4Market Challenges
3.3Porter Five Forces Analysis

Chapter 4.North America Diabetic Neuropathy Treatment Market by Distribution Channel

4.1North America Hospitals Pharmacies Market by Country
4.2North America Retail Pharmacies Market by Country
4.3North America Others Market by Country

Chapter 5.North America Diabetic Neuropathy Treatment Market by Drug Class

5.1North America Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
5.2North America Antidepressants Market by Country
5.3North America Opioid Market by Country
5.4North America Capsaicin Market by Country
5.5North America Others Market by Country

Chapter 6.North America Diabetic Neuropathy Treatment Market by Disorder Type

6.1North America Peripheral Neuropathy Market by Country
6.2North America Autonomic Neuropathy Market by Country
6.3North America Proximal Neuropathy Market by Country
6.4North America Focal Neuropathy Market by Country

Chapter 7.North America Diabetic Neuropathy Treatment Market by Country

7.1US Diabetic Neuropathy Treatment Market
- 7.1.1US Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.1.2US Diabetic Neuropathy Treatment Market by Drug Class
- 7.1.3US Diabetic Neuropathy Treatment Market by Disorder Type
7.2Canada Diabetic Neuropathy Treatment Market
- 7.2.1Canada Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.2Canada Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.3Canada Diabetic Neuropathy Treatment Market by Disorder Type
7.3Mexico Diabetic Neuropathy Treatment Market
- 7.3.1Mexico Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.2Mexico Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.3Mexico Diabetic Neuropathy Treatment Market by Disorder Type
7.4Rest of North America Diabetic Neuropathy Treatment Market
- 7.4.1Rest of North America Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.2Rest of North America Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.3Rest of North America Diabetic Neuropathy Treatment Market by Disorder Type

Chapter 8.Company Profiles

8.1Abbott Laboratories
- 8.1.1Company Overview
- 8.1.2Financial Analysis
- 8.1.3Segmental and Regional Analysis
- 8.1.4Research & Development Expense
- 8.1.5Recent strategies and developments:
  - 8.1.5.1Acquisition and Mergers:
  - 8.1.5.2Trial and Approval:
- 8.1.6SWOT Analysis
8.2Eli Lilly And Company
- 8.2.1Company Overview
- 8.2.2Financial Analysis
- 8.2.3Regional Analysis
- 8.2.4Research & Development Expenses
- 8.2.5Recent strategies and developments:
  - 8.2.5.1Acquisition and Mergers:
- 8.2.6SWOT Analysis
8.3Pfizer, Inc.
- 8.3.1Company Overview
- 8.3.2Financial Analysis
- 8.3.3Regional & Segmental Analysis
- 8.3.4Research & Development Expense
- 8.3.5SWOT Analysis
8.4Lupin Limited
- 8.4.1Company Overview
- 8.4.2Financial Analysis
- 8.4.3Regional Analysis
- 8.4.4Research & Development Expense
- 8.4.5SWOT Analysis
8.5Astellas Pharma, Inc.
- 8.5.1Company Overview
- 8.5.2Financial Analysis
- 8.5.3Regional Analysis
- 8.5.4Research & Development Expense
- 8.5.5SWOT Analysis
8.6Glenmark Pharmaceuticals Limited
- 8.6.1Company Overview
- 8.6.2Financial Analysis
- 8.6.3Regional Analysis
- 8.6.4Research & Development Expenses
- 8.6.5SWOT Analysis
8.7Boehringer Ingelheim International GmbH
- 8.7.1Company Overview
- 8.7.2Financial Analysis
- 8.7.3Regional & Segmental Analysis
- 8.7.4Research & Development Expenses
- 8.7.5SWOT Analysis
8.8Novartis AG
- 8.8.1Company Overview
- 8.8.2Financial Analysis
- 8.8.3Segmental and Regional Analysis
- 8.8.4Research & Development Expense
- 8.8.5Recent strategies and developments:
  - 8.8.5.1Acquisition and Mergers:
- 8.8.6SWOT Analysis
8.9McKesson Corporation
- 8.9.1Company Overview
- 8.9.2Financial Analysis
- 8.9.3Segmental Analysis
- 8.9.4Research & Development Expense
- 8.9.5SWOT Analysis
8.10.GlaxoSmithKline PLC (GSK)
- 8.10.1Company Overview
- 8.10.2Financial Analysis
- 8.10.3Regional Analysis
- 8.10.4Research & Development Expense
- 8.10.5SWOT Analysis

LIST OF TABLES

TABLE 1North America Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 2North America Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 3North America Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 4North America Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 5North America Hospitals Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 6North America Hospitals Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 7North America Retail Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 8North America Retail Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 9North America Others Market by Country, 2020 - 2023, USD Million
TABLE 10North America Others Market by Country, 2024 - 2031, USD Million
TABLE 11North America Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 12North America Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 13North America Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2020 - 2023, USD Million
TABLE 14North America Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2024 - 2031, USD Million
TABLE 15North America Antidepressants Market by Country, 2020 - 2023, USD Million
TABLE 16North America Antidepressants Market by Country, 2024 - 2031, USD Million
TABLE 17North America Opioid Market by Country, 2020 - 2023, USD Million
TABLE 18North America Opioid Market by Country, 2024 - 2031, USD Million
TABLE 19North America Capsaicin Market by Country, 2020 - 2023, USD Million
TABLE 20North America Capsaicin Market by Country, 2024 - 2031, USD Million
TABLE 21North America Others Market by Country, 2020 - 2023, USD Million
TABLE 22North America Others Market by Country, 2024 - 2031, USD Million
TABLE 23North America Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 24North America Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 25North America Peripheral Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 26North America Peripheral Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 27North America Autonomic Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 28North America Autonomic Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 29North America Proximal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 30North America Proximal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 31North America Focal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 32North America Focal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 33North America Diabetic Neuropathy Treatment Market by Country, 2020 - 2023, USD Million
TABLE 34North America Diabetic Neuropathy Treatment Market by Country, 2024 - 2031, USD Million
TABLE 35US Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 36US Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 37US Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 38US Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 39US Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 40US Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 41US Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 42US Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 43Canada Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 44Canada Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 45Canada Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 46Canada Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 47Canada Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 48Canada Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 49Canada Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 50Canada Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 51Mexico Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 52Mexico Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 53Mexico Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 54Mexico Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 55Mexico Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 56Mexico Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 57Mexico Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 58Mexico Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 59Rest of North America Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 60Rest of North America Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 61Rest of North America Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 62Rest of North America Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 63Rest of North America Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 64Rest of North America Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 65Rest of North America Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 66Rest of North America Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 67Key Information - Abbott Laboratories
TABLE 68Key Information - Eli Lilly And Company
TABLE 69Key Information - Pfizer, Inc.
TABLE 70Key Information - Lupin Limited
TABLE 71key information - Astellas Pharma, Inc.
TABLE 72Key Information - Glenmark Pharmaceuticals Limited
TABLE 73Key Information - Boehringer Ingelheim International GmbH
TABLE 74Key Information - Novartis AG
TABLE 75Key Information - McKesson Corporation
TABLE 76Key Information - GlaxoSmithKline PLC

North America Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024 - 2031

Description

Table of Contents